BuSpar patent appeal
Executive Summary
U.S. appeals court to hear oral arguments on BuSpar patent infringement lawsuit July 12. The court earlier denied Bristol-Myers Squibb's motion for a stay of the D.C. federal court's order to delist a BuSpar metabolite patent from the "Orange Book" and approve generic buspirone (1"The Pink Sheet" April 2, p. 28). Mylan filed suit against Bristol and FDA Nov. 30
U.S. appeals court to hear oral arguments on BuSpar patent infringement lawsuit July 12. The court earlier denied Bristol-Myers Squibb's motion for a stay of the D.C. federal court's order to delist a BuSpar metabolite patent from the "Orange Book" and approve generic buspirone (1 (Also see "Par 7.5 Mg Buspirone Aims To Capture Portion of 15 Mg Split-Tablet Market" - Pink Sheet, 2 Apr, 2001.)). Mylan filed suit against Bristol and FDA Nov. 30. |